Analytical Data
-
Gene name
USP18
- Application
-
Alternative Names
USP18；ISG43；Ubl carboxyl-terminal hydrolase 18
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9UMW8
-
Expression Region
1-372aa
-
AA Sequence
MSKAFGLLRQICQSILAESSQSPADLEEKKEEDSNMKREQPRERPRAWDYPHGLVGLHNIGQTCCLNSLIQVFVMNVDFTRILKRITVPRGADEQRRSVPFQMLLLLEKMQDSRQKAVRPLELAYCLQKCNVPLFVQHDAAQLYLKLWNLIKDQITDVHLVERLQALYTIRVKDSLICVDCAMESSRNSSMLTLPLSLFDVDSKPLKTLEDALHCFFQPRELSSKSKCFCENCGKKTRGKQVLKLTHLPQTLTIHLMRFSIRNSQTRKICHSLYFPQSLDFSQILPMKRESCDAEEQSGGQYELFAVIAHVGMADSGHYCVYIRNAVDGKWFCFNDSNICLVSWEDIQCTYGNPNYHWQETAYLLVYMKMEC
-
Molecular Weight
50.5 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
USP18 (Ubiquitin-Specific Peptidase 18) is a member of the USP family of deubiquitinating enzymes, which play critical roles in regulating various cellular processes by removing ubiquitin from proteins. The study of USP18 has gained significant attention due to its involvement in multiple biological pathways, particularly in the context of immune response and inflammation. It acts as a negative regulator of the antiviral response by deubiquitinating components of the interferon signaling pathway, thereby influencing the host's susceptibility to viral infections. Research indicates that USP18 can modulate the activity of important signaling molecules like JAK1 and STAT, impacting the efficacy of type I interferons. Dysregulation of USP18 has been implicated in several diseases, including autoimmune disorders and cancer, highlighting its potential as a therapeutic target. Additionally, understanding the structural and functional properties of USP18 can provide insights into its mechanism of action, paving the way for the development of novel inhibitors or modulators that could enhance antiviral therapies or counteract aberrant immune responses. As such, studies focused on USP18 recombinant protein aim to elucidate its role in disease mechanisms and therapeutic interventions, making it a compelling subject for ongoing and future research in molecular biology and pharmacology.
